Physician profile
David O Chee
NPI 1467680405
$12,280.87
in general payments reported to CMS, 2019-2025
21 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $1,795 · 2021: $1,869 · 2022: $1,654 · 2023: $1,761 · 2024: $1,547 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,990 · Education: $21.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,989.82 |
| Education | $21.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,916.58 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $2,228.20 | 2019-2025 | Veklury, Biktarvy |
| Abbvie INC. | $712.63 | 2021-2025 | Avycaz, Teflaro |
| Janssen Biotech, INC. | $654.14 | 2019-2023 | Symtuza |
| Allergan, INC. | $628.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $602.74 | 2019-2025 | Prevymis, Zerbaxa, Dificid |
| Paratek Pharmaceuticals, INC. | $499.44 | 2019-2025 | Nuzyra |
| Insmed, INC. | $412.15 | 2019-2023 | Arikayce |
| Shionogi INC | $401.07 | 2021-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $342.39 | 2021-2025 | Xacduro, Zevtera, Xerava |
| Melinta Therapeutics, LLC | $175.19 | 2019-2024 | Kimyrsa, Rezzayo |
| Ferring Pharmaceuticals INC. | $141.41 | 2022-2023 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $126.41 | 2019-2023 | Vibativ |
| Astellas Pharma US INC | $101.70 | 2023-2025 | Cresemba |
| Aimmune Therapeutics, INC. | $92.79 | 2024-2025 | Vowst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56.96 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $51.30 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.71 | 2022-2024 | Livtencity |
| Tetraphase Pharmaceuticals, INC. | $39.54 | 2019 | |
| Emd Serono, INC. | $33.60 | 2025 | |
| Theratechnologies INC. | $18.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.